Novonix (ASX: NVX) adds 129m placement shares at A$0.16 each

Rhea-AI Filing Summary

Novonix Limited has applied to quote 129,334,163 new ordinary fully paid shares on the ASX. These shares were issued as part of a previously announced placement and are priced at AUD 0.16 per share, with an issue date of June 22, 2026.

After quotation, Novonix will have 991,561,920 ordinary shares on issue. The company also has unquoted instruments on issue, including 27,401,382 performance rights, 14,016,667 options, 1,371,566 share rights, 45,221,586 convertible notes and 35,000,000 convertible debentures, which together outline additional potential equity overhang.

Insights

Equity capital markets analyst

Novonix adds 129m new shares at A$0.16, expanding equity base.

Novonix Limited is completing a previously announced placement, issuing 129,334,163 ordinary shares at AUD 0.16 each, to be quoted on the ASX with an issue date of June 22, 2026. This increases the quoted share count to 991,561,920 ordinary shares.

The filing also lists sizeable unquoted instruments: performance rights, options, share rights, and convertible securities, including 45,221,586 convertible notes and 35,000,000 convertible debentures. These instruments represent potential future share issuance depending on their individual terms.

The placement meaningfully expands the equity base and introduces near-term dilution for existing holders, while the unquoted rights and convertibles add longer-term dilution risk. Actual impact depends on how and when these additional securities vest, convert, or are exercised under their respective terms.

Key Figures

Placement shares: 129,334,163 shares Issue price: AUD 0.16 per share Total quoted shares: 991,561,920 shares +4 more

7 metrics

Placement shares 129,334,163 shares Ordinary fully paid shares to be quoted, issue date June 22, 2026

Issue price AUD 0.16 per share Cash consideration for new ordinary shares

Total quoted shares 991,561,920 shares Ordinary fully paid shares on issue after quotation

Performance rights 27,401,382 rights Unquoted NVXAD performance rights on issue

Options 14,016,667 options Unquoted NVXAA options expiring on various dates

Convertible notes 45,221,586 notes Unquoted NVXAL convertible notes on issue

Convertible debentures 35,000,000 debentures Unquoted NVXAH convertible debentures on issue

Key Terms

Appendix 2A, Appendix 3B, performance rights, convertible notes, +2 more

6 terms

Appendix 2A regulatory

"We apply for quotation of the following securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules."

Appendix 3B regulatory

"Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B."

performance rights financial

"NVXAD PERFORMANCE RIGHTS | 27,401,382"

Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.

convertible notes financial

"NVXAL CONVERTIBLE NOTES | 45,221,586"

Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.

convertible debentures financial

"NVXAH CONVERTIBLE DEBENTURES | 35,000,000"

Convertible debentures are loans a company issues that pay interest like a bond but can be swapped later for the company’s shares at a set price. For investors they act like a safety-net plus a shortcut: you get regular interest payments while retaining the option to join ownership if the share price rises, which offers upside potential but can dilute existing shareholders if conversion occurs.

share rights financial

"NVXAM SHARE RIGHTS | 1,371,566"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/22/2026 - 06:56 AM Accepted by SEC EDGAR 06/22/2026 - 06:56 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2026

001-41208

(Commission File Number)

NOVONIX LIMITED

(Translation of registrant’s name into English)

Level 38

71 Eagle Street

Brisbane, QLD 4000 Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40‑F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit No.		Description
Exhibit 99.1		Appendix 2A (Application for quotation of securities) dated June 19, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVONIX LIMITED
By:	/s/ Robert Long
	Robert Long
	Chief Financial Officer

Date: June 22, 2026

Appendix 2A - Application for quotation of securities

Exhibit 99.1

Announcement Summary

Entity name

NOVONIX LIMITED

Announcement Type

New announcement

Date of this announcement

Friday June 19, 2026

The +securities to be quoted are:

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B

Total number of +securities to be quoted

	ASX +security code	Security description	Number of +securities to be quoted Issue date
	NVX	ORDINARY FULLY PAID	129,334,163 22/06/2026

Refer to next page for full details of the announcement

Appendix 2A - Application for quotation of securities 1 / 5

Appendix 2A - Application for quotation of securities

Part 1 - Entity and announcement details

1.1 Name of entity

NOVONIX LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type	Registration number
ABN	54157690830

1.3 ASX issuer code

NVX

1.4 The announcement is

New announcement

1.5 Date of this announcement

19/6/2026

Appendix 2A - Application for quotation of securities 2 / 5

Appendix 2A - Application for quotation of securities

Part 2 - Type of Issue

2.1 The +securities to be quoted are:

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B

Previous Appendix 3B details:

Announcement Date and Time	Announcement Title	Selected Appendix 3B to submit quotation request
17-Jun-2026 10:03	New - Proposed issue of securities - NVX	A placement or other type of issue

2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?

Yes

2.3a.3 Please provide details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B

Shares still to be issued under the securities purchase plan.

Appendix 2A - Application for quotation of securities 3 / 5

Appendix 2A - Application for quotation of securities

Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B

Placement Details

ASX +security code and description

NVX : ORDINARY FULLY PAID

Issue date

22/6/2026

Issue details

Number of +securities to be quoted

129,334,163

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?	What is the issue price per +security?
AUD - Australian Dollar	AUD 0.16000000

Any other information the entity wishes to provide about the +securities to be quoted

Appendix 2A - Application for quotation of securities 4 / 5

Appendix 2A - Application for quotation of securities

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the

+securities subject of this application)

ASX +security code and description	Total number of +securities on issue
NVX : ORDINARY FULLY PAID	991,561,920

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
NVXAD : PERFORMANCE RIGHTS	27,401,382
NVXAA : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	14,016,667
NVXAM : SHARE RIGHTS	1,371,566
NVXAL : CONVERTIBLE NOTES	45,221,586
NVXAH : CONVERTIBLE DEBENTURES	35,000,000

Appendix 2A - Application for quotation of securities 5 / 5

FAQ

What did Novonix (NVX) announce in its June 2026 Form 6-K?

Novonix announced the quotation of 129,334,163 new ordinary fully paid shares on the ASX. These shares were issued under a previously announced placement and are priced at AUD 0.16 per share, with an issue date of June 22, 2026.

How many Novonix (NVX) shares will be on issue after this placement?

Following quotation of the new placement shares, Novonix will have 991,561,920 ordinary fully paid shares on issue. This figure reflects the expanded equity base after the 129,334,163 new shares are added to the company’s quoted capital.

What is the issue price of the new Novonix (NVX) placement shares?

The new Novonix ordinary shares are being issued at AUD 0.16 per share. This price applies to the 129,334,163 shares forming part of the previously announced placement that are now being quoted on the ASX.

Are there additional Novonix (NVX) securities that could convert into shares?

Yes. Novonix has several unquoted instruments on issue, including 27,401,382 performance rights, 14,016,667 options, 45,221,586 convertible notes and 35,000,000 convertible debentures, each of which may lead to future share issuance under their terms.

What ASX forms are referenced in Novonix’s (NVX) June 2026 announcement?

The announcement is an Appendix 2A application for quotation of securities, linked to a previously lodged Appendix 3B for a proposed issue. It details the 129,334,163 placement shares at AUD 0.16 and resulting issued capital.

Does the Novonix (NVX) filing indicate further issues to complete the transaction?

Yes. The document notes there are further issues of securities yet to take place to complete the transactions described in the Appendix 3B, indicating the placement-related capital-raising process is not entirely finished in this single tranche.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 82.4 KB